Hiprex trial for recurrent UTIs halted early – little data to go on

NCT ID NCT04709601

Terminated Disease control Sponsor: University of Texas Southwestern Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study aimed to see if Hiprex (methenamine hippurate) could reduce recurrent urinary tract infections in women aged 50 to 85. Participants took Hiprex daily for a year, and researchers counted infections and antibiotic use. However, the trial was terminated early with only 14 participants, so we have very limited information on whether it works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: methenamine hippurate (Hiprex)
What this could lead to: If it worked, this could offer a non-antibiotic option to reduce recurrent urinary tract infections in older women.
What could go wrong: The trial was terminated early and enrolled only 14 participants, so results are very limited. It is unclear if Hiprex effectively prevents UTIs or reduces antibiotic use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT URINARY TRACT INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

urinary tract infection urinary tract infections, recurrent, susceptibility to

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

URINARY TRACT INFECTIONS

Contacts and locations

Locations

UT-Southwestern Medical Center

Dallas, Texas, 75390, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.